AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial
M. Scott Harris(Altimmune (United States)), Barbara S. Fox(Avaxia Biologics (United States)), Theadore Ptak, Emma Erlich(Avaxia Biologics (United States)), Sharon Spence(Avaxia Biologics (United States)), Sally Kennedy(Avaxia Biologics (United States)), Ronald E. Pruitt(Nashville Medical Research Institute), Hartman Deborah(Avaxia Biologics (United States)), Brenda Lemos(Avaxia Biologics (United States)), Séverine Vermeire(KU Leuven)
Cited by 75
Related Papers
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
|The Lancet|2015|776
Ribosome Profiling Reveals Pervasive Translation Outside of Annotated Protein-Coding Genes
|Cell Reports|2014|678
Identification of Long-Lived Proteins Reveals Exceptional Stability of Essential Cellular Structures
|Cell|2013|603
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility
|Nature Genetics|2008|523